Literature DB >> 31914207

The protective potential of Fc-mediated antibody functions against influenza virus and other viral pathogens.

Hillary A Vanderven1,2, Stephen J Kent2,3,4.   

Abstract

In recent years, there has been a renewed interest in utilizing antibody fragment crystallizable (Fc) functions to prevent and control viral infections. The protective and therapeutic potential of Fc-mediated antibody functions have been assessed for some clinically important human viruses, including HIV, hemorrhagic fever viruses and influenza virus. There is mounting evidence that influenza-specific antibodies with Fc-mediated functions, such as antibody-dependent cellular cytotoxicity and antibody-dependent phagocytosis, can aid in the clearance of influenza virus infection. Recent influenza challenge studies and intravenous immunoglobulin G therapy studies in humans suggest a protective role for Fc effector functions in vivo. Broadly reactive influenza antibodies with Fc-mediated functions are prevalent in the human population and could inform the development of a universally protective influenza vaccine or therapy. In this review, we explore the utility of antibodies with Fc-mediated effector functions against viral infections with a focus on influenza virus.
© 2020 Australian and New Zealand Society for Immunology Inc.

Entities:  

Keywords:  Antibodies; Fc receptors; antibody-dependent cellular cytotoxicity; antibody-dependent phagocytosis; influenza virus; natural killer cells

Year:  2020        PMID: 31914207     DOI: 10.1111/imcb.12312

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  14 in total

1.  Engineered Nanoparticulate Vaccines to Combat Recurring and Pandemic Influenza Threats.

Authors:  Chunhong Dong; Bao-Zhong Wang
Journal:  Adv Nanobiomed Res       Date:  2021-12-07

2.  Murine Cross-Reactive Nonneutralizing Polyclonal IgG1 Antibodies Induced by Influenza Vaccine Inhibit the Cross-Protective Effect of IgG2 against Heterologous Virus in Mice.

Authors:  Meito Shibuya; Taiki Aoshi; Etsushi Kuroda; Yasuo Yoshioka
Journal:  J Virol       Date:  2020-06-01       Impact factor: 5.103

3.  FcγR Genetic Variation and HIV-1 Vaccine Efficacy: Context And Considerations.

Authors:  Ria Lassaunière; Caroline T Tiemessen
Journal:  Front Immunol       Date:  2021-12-15       Impact factor: 7.561

Review 4.  Protein engineering strategies for rational immunogen design.

Authors:  Timothy M Caradonna; Aaron G Schmidt
Journal:  NPJ Vaccines       Date:  2021-12-17       Impact factor: 7.344

5.  Immunogenicity and protective efficacy of a recombinant protein subunit vaccine and an inactivated vaccine against SARS-CoV-2 variants in non-human primates.

Authors:  Qian He; Qunying Mao; Xiaozhong Peng; Zhanlong He; Shuaiyao Lu; Jialu Zhang; Fan Gao; Lianlian Bian; Chaoqiang An; Wenhai Yu; Fengmei Yang; Yanan Zhou; Yun Yang; Yanyan Li; Yadi Yuan; Xujia Yan; Jinghuan Yang; Xing Wu; Weijin Huang; Changgui Li; Junzhi Wang; Zhenglun Liang; Miao Xu
Journal:  Signal Transduct Target Ther       Date:  2022-03-03

6.  Polycationic HA/CpG Nanoparticles Induce Cross-Protective Influenza Immunity in Mice.

Authors:  Chunhong Dong; Ye Wang; Wandi Zhu; Yao Ma; Joo Kim; Lai Wei; Gilbert X Gonzalez; Bao-Zhong Wang
Journal:  ACS Appl Mater Interfaces       Date:  2022-01-27       Impact factor: 9.229

7.  Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population.

Authors:  Sabra L Klein; Andrew Pekosz; Han-Sol Park; Rebecca L Ursin; Janna R Shapiro; Sarah E Benner; Kirsten Littlefield; Swetha Kumar; Harnish Mukesh Naik; Michael J Betenbaugh; Ruchee Shrestha; Annie A Wu; Robert M Hughes; Imani Burgess; Patricio Caturegli; Oliver Laeyendecker; Thomas C Quinn; David Sullivan; Shmuel Shoham; Andrew D Redd; Evan M Bloch; Arturo Casadevall; Aaron Ar Tobian
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

8.  Contribution of Antibody-Mediated Effector Functions to the Mechanism of Efficacy of Vaccines for Opioid Use Disorders.

Authors:  April M Huseby Kelcher; Carly A Baehr; Fatima A Hamid; Geoffrey T Hart; Marco Pravetoni
Journal:  J Immunol       Date:  2021-07-19       Impact factor: 5.426

Review 9.  Behavioral strategies to prevent and mitigate COVID-19 infection.

Authors:  Noah T Hutchinson; Andrew Steelman; Jeffrey A Woods
Journal:  Sports Med Health Sci       Date:  2020-09-10

Review 10.  Broad Reactivity Single Domain Antibodies against Influenza Virus and Their Applications to Vaccine Potency Testing and Immunotherapy.

Authors:  Andrew Tung Yep; Yasu Takeuchi; Othmar G Engelhardt; Simon E Hufton
Journal:  Biomolecules       Date:  2021-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.